UWPG
MYGN icon

Ullmann Wealth Partners Group’s Myriad Genetics MYGN Stock Holding History

Ullmann Wealth Partners Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-416
Closed -$10K – 104
2017
Q2 		$10K Hold
416
– – 0.01% 140
2017
Q1 		$7K Buy
+416
New +$7.37K 0.01% 135

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Ullmann Wealth Partners Group's MYGN Position: Q3 2017 in Review

Ullmann Wealth Partners Group sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 416 shares — an estimated $10K sold.

Ullmann Wealth Partners Group first reported a position in MYGN in Q1 2017 and held it in 2 quarters. The position peaked at $10K in Q2 2017. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • Ullmann Wealth Partners Group reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
  • Ullmann Wealth Partners Group sold 416 Myriad Genetics shares in Q3 2017, an estimated $10K.
  • Ullmann Wealth Partners Group first reported a position in Myriad Genetics in Q1 2017 and held it in 2 quarters.
  • Ullmann Wealth Partners Group's Myriad Genetics position peaked at $10K in Q2 2017.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Ullmann Wealth Partners Group's 13F filing for Q3 2017, filed 14 Nov 2017.